眼科 ›› 2024, Vol. 33 ›› Issue (1): 47-51.doi: 10.13281/j.cnki.issn.1004-4469.2024.01.008

• 论著 • 上一篇    下一篇

玻璃体注射化疗对存在玻璃体种植的视网膜母细胞瘤的21个月疗效观察

李程  张诚玥  崔燕辉  李莉   

  1. 首都医科大学附属北京儿童医院眼科 国家儿童医学中心,北京 100045
  • 收稿日期:2023-10-11 出版日期:2024-01-25 发布日期:2024-02-06
  • 通讯作者: 李莉,Email:liliyk1@163.com

Twenty-one months efficacy of intravitreal chemotherapy for retinoblastoma with vitreous seeding

Li Cheng, Zhang Chengyue, Cui Yanhui, Li Li   

  1. Department of Ophthalmology, Beijing Children’s Hospital, National Center for Children’s Health, Beijing 100045, China
  • Received:2023-10-11 Online:2024-01-25 Published:2024-02-06
  • Contact: LiLi, Email:liliyk1@163.com

摘要: 目的 探讨玻璃体注射化疗对存在玻璃体种植的视网膜母细胞瘤的临床疗效。设计 回顾性病例系列。研究对象v2019年10月至2020年10月在北京儿童医院诊断和治疗的单眼cT2期视网膜母细胞瘤患者18例(18眼)。方法 根据患眼玻璃体种植病灶的形态学特点分为1型尘埃样和2型球形。所有患者均接受了玻璃体注射化疗(左旋苯丙氨酸氮芥)。记录患者玻璃体注射化疗的次数,玻璃体种植瘤灶的消退时间、随访时间、是否出现手术相关并发症、是否存在肿瘤眼外转移等,并计算患者的保眼率。不同类型玻璃体种植组间注射次数和玻璃体种植瘤灶消退时间的比较采用秩和检验。主要指标  玻璃体注射化疗的次数,玻璃体种植瘤灶的消退时间、随访时间、是否出现手术相关并发症、是否存在肿瘤眼外转移,保眼率。结果 18例(18眼)单眼cT2期视网膜母细胞瘤患者中,10例(10眼)玻璃体种植病灶呈尘埃样(1型),8例(8眼)呈球形(2型)。经玻璃体注射化疗,所有患眼玻璃体种植瘤灶全部消退。在治疗和随访中,有8例(44.4%)在玻璃体注射位置周围出现椒盐样视网膜病变;2例(11.1%)出现玻璃体少量出血。未观察到肿瘤的眼外转移及死亡。随访(21.08±2.18)个月。1型和2型玻璃体种植接受玻璃体注射化疗次数的中位数分别为2.5次(2,3)和5.5次(5,6)(Z=-3.679,P<0.05),消退时间的中位数分别为1.875个月(1.56,2.00)和3.875个月(3.50,4.06)(Z=-3.586,P<0.05)。结论  玻璃体注射化疗是针对存在玻璃体肿瘤种植的视网膜母细胞瘤的有效治疗手段。(眼科,2024, 33: 47-51)

关键词:  , 视网膜母细胞瘤;玻璃体注射化疗

Abstract: Objective To explore the clinical efficacy of intravitreal chemotherapy for retinoblastoma with vitreous seeding. Design  Retrospectvie case series. Participants 18 patients (18 eyes) unilateral group cT2 retinoblastoma patients diagnosed and treated at Beijing Children’s Hospital from October 2019 to October 2020 were recruited. Methods According to the morphological characteristics of vitreous implant lesions, the patients were divided into type 1 (dust-like) and type 2 (spherical). All the patients received intravitreal injection of melphalan. Number of intravitreal injection, time to regression of vitreous seeds, follow-up time, complications related to surgery and extraocular extension were recorded. Globe salvage rate were computed. Number of intravitreal injection and time to regression of vitreous seeds in different group were compared with rank sum test. Main Outcome Measures The Times of intravitreal chemotherapy, the regression time of vitreous implantation tumor, the follow-up time, the occurrence of surgery-related complications, the presence of extraocular metastasis of tumor, and the eye preservation rate. Results Among 18 patients (18 eyes) unilateral group cT2 retinoblastoma patients, the morphologic feature of vitreous seeds was dustlike (type1) in 10 patients (10 eyes), was spherelike (type 2) in 8 patients (8 eyes). Vitreous seeds of all patients regressed after intravitreal injection of melphalan. During the treatment and follow-up period, 8 eyes (44.4%) had pepper-and-salt retinopathy close to the injection location in the retina and 2 eyes(11.1%) had mild vitreous hemorrhage. No patient died or had extraocular extension. The follow-up time was (21.08±2.18)months. The median number of intravitreal injection for type 1 and type 2 was 2.5(2, 3) and 5.5(5, 6), respectively (Z=-3.679, P<0.05). The median time to regression of vitreous seeds for type 1 and type 2 was 1.875 months(1.56,2.00) and 3.875 months(3.50, 4.06), respectively (Z=-3.586, P<0.05). Conclusion Intravitreal chemotherapy is the very effective treatment modality for retinoblastoma with vitreous seeds. (Ophthalmol CHN, 2024, 33: 47-51)

Key words: retinoblastoma, intravitreal chemotherapy